Tempest Therapeutics Inc. stocks have been trading up by 42.8 percent following highly promising clinical trial advancement news.
Click Here for a Millionaire's POV on Trading TPST
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Tempest Therapeutics signed an exclusive option with Hebei Senlang for a CD7-targeted lentiviral in vivo CAR-T platform and a BCMA/GPRC5D dual-targeting CAR-T already in Phase 1 for hard-to-treat myeloma.
- Shares of TPST jumped about 35% after-hours after the Senlang option news and a roughly $2.5M warrant-based private placement hit the tape.
- The Senlang deal is set to complement Tempest Therapeutics’ own CD7-targeted LNP in vivo CAR-T platform and broaden its “immune reset” pipeline across cancers and autoimmune diseases.
- Management plans to spotlight TPST-4003 and the in vivo CAR-T platform at the H.C. Wainwright 28th Annual Global Investment Conference, adding a near-term narrative catalyst.
Live Update At 09:18:39 EDT: On Wednesday, September 16, 2026 Tempest Therapeutics Inc. stock [NASDAQ: TPST] is trending up by 42.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TPST is still a classic early-stage biotech story: heavy on R&D, light on revenue, and burning cash fast. Tempest Therapeutics reported Q2 2026 net loss of about $5.2M, or roughly -$0.34 per share, driven by $1.8M in research expense and $3.4M in G&A. For traders, that signals a development-stage name where the chart moves on headlines, not earnings beats.
Operating cash flow for Tempest Therapeutics came in around -$2.8M for the quarter, with free cash flow matching that figure. End-of-period cash was only about $1.2M, and TPST showed negative working capital of roughly $2.8M. That explains why management leaned on a $2.5M private placement tied to the Senlang option news.
More Breaking News
- ServiceTitan TTAN Stock Grinds Higher As Bears Back Off
- AXTI Stock Jumps As S&P SmallCap 600 Inclusion Fuels Momentum
- PACB Stock Grinds Higher As Traders Eye Morgan Stanley Chat
- HPE Stock Surges As AI Deals And Guidance Reset Bull Case
On the balance sheet, Tempest Therapeutics carries about $6.3M in long-term debt and negative equity of roughly $1.1M, with leverage ratios that look aggressive. Return on assets and equity are deeply negative, underscoring that TPST is a high-risk development play. For active trading, that mix—thin cash, high burn, binary clinical catalysts—often means sharp moves in both directions when news hits.
Why Traders Are Watching TPST After The Senlang Deal
Traders flocked to TPST after Tempest Therapeutics announced its exclusive option with Hebei Senlang Biotechnology. The headline: control of a CD7-targeted lentiviral in vivo CAR-T platform plus a portfolio of candidates, including a BCMA/GPRC5D dual-targeting CAR-T already in Phase 1 dose escalation for relapsed or refractory multiple myeloma. That’s not just another preclinical idea. It is real clinical-stage exposure in a red-hot area of cell therapy.
The deal matters because Tempest Therapeutics already has its own CD7-targeted LNP in vivo CAR-T platform. By layering Senlang’s lentiviral platform on top, TPST is effectively building a broader toolkit around its “immune reset” strategy across hematologic cancers and autoimmune disease. Traders see synergy here, not simple pipeline bloat.
The market reaction confirms it. On the same day Tempest Therapeutics locked in the option, TPST also raised about $2.5M via a warrant-based private placement. That is a small raise, but it came alongside a 35% after-hours spike in TPST shares. That combo says the tape cared more about the platform expansion than the dilution.
For short-term trading, this is exactly the setup the TPST crowd hunts: low-priced biotech, tight float dynamics, and a clear, easy-to-understand catalyst—“new CAR-T deal, Phase 1 asset, stock rips.” Add another catalyst ahead as Tempest Therapeutics presents at the H.C. Wainwright 28th Annual Global Investment Conference, spotlighting TPST-4003 and the in vivo CAR-T story, and you’ve got a narrative that can stay hot as long as the headlines keep coming.
Conclusion
Under the hood, TPST still looks like a fragile biotech. Tempest Therapeutics has negative equity, limited cash, and a quarterly cash burn that forces it to keep tapping the market. The key ratios—weak current ratio, heavy leverage, deeply negative returns—tell traders that balance-sheet risk is real and ever-present.
But this is exactly why TPST can move so violently on news. When Tempest Therapeutics signs an exclusive option on a clinical-stage in vivo CAR-T platform, and pairs it with a modest capital raise, the story shifts from “how long until they run out of cash” to “how big can this immune reset pipeline get.” That is what drove the 35% after-hours surge, even as the underlying numbers remain rough.
Technically, TPST has been in a downtrend on the daily chart, sliding from the $1.10–$1.20 area toward the mid-$0.70s before this deal hit. That sets up classic “former runner, beaten down, fresh catalyst” price action that momentum traders love to stalk. Tempest Therapeutics will now be judged bar-by-bar on how much data, partnerships, or additional capital it can pull out of this new Senlang relationship and its TPST-4003 program.
As Tim Sykes likes to hammer home, “Big news plus a low-priced stock can create wild moves, but the only way to survive is to cut losses quickly and never believe the hype.” As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.”. TPST fits that playbook perfectly—high potential story, high risk profile, and a chart that rewards disciplined traders who treat it as an educational case study, not a sure thing.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.